Introduction
Cefoxitin is a semisynthetic cephamycin antibiotic which has recently been made available for clinical trial. Cephamycins differ from the cephalosporins in that they have an x-methoxy group in the 7-position of the structure of the molecule.' Cefoxitin also has a carbamoyloxy group in the 3-position of the molecule.' While the cephalosporins are labile to the 3-lactamases of many Gram-negative organisms, cefoxitin is stable to degradation by these enzymes.3 Cefoxitin has greater activity than the cephalosporins against most Gram-negative bacilli including indole-producing Proteus spp and Serratia marcescens, which are normally cephalosporin-resistant, but is less active against Gram-positive organisms. 3'6 Cefoxitin is also active against anaerobic organisms including Bacteroides fragilis.7 Pharmacokinetic studies in volunteers have shown that serum and urine concentrations of cefoxitin are higher and more sustained than those obtained after equivalent doses of cephalothin. 3 We studied the toxicological and pharmacological effects of cefoxitin on 31 hospital patients with various acute infections.
Patients and methods
Thirty-one hospital inpatients suffering from various acute infections were selected for treatment with cefoxitin ( dose of cefoxitin ranged from 1 g eight-hourly to 2 g six-hourly. The minimum total dose was 8 g and maximum total dose 54 g. In all patients before, during, and after cefoxitin treatment full blood count was taken, Coombs's test, urine analysis, and liver function tests were performed, and serum urea and creatinine concentrations were measured.
PHARMACOLOGY
Serum cefoxitin concentrations were measured in seven and urine concentrations in four of the 21 patients after intravenous injection of the antibiotic over three minutes. In two patients with postcholecystectomy T-tube drainage cefoxitin concentrations in bile were assayed. Two grams of cefoxitin were given to two patients before lumbar puncture and the cerebrospinal fluid (CSF) was collected one hour after injection and tested for antibiotic activity. One of the patients had meningoencephalitis but the other was subsequently found to have no disease of the central nervous system. Cefoxitin concentration in breast milk was measured in a lactating woman being treated with the drug for a urinary tract infection. Cefoxitin assays were performed using a plate assay method with Penassay media No 1 (Difco) using a Bacillus suibtilis spore suspension.
Results
Twenty of the 31 patients were cured by cefoxitin, while a further five responded satisfactorily (table I) but the infecting organism either persisted in the sputum (three patients) or reappeared after treatment (two patients). The remaining six patients were considered to be treatment failures. Two of these were elderly women with urinary tract infections, two had respiratory tract infections, and two had septicaemia. In the two patients with chest infections who failed to respond to cefoxitin we could not obtain a bacteriological diagnosis before treatment, although th. sputum had been frankly purulent and there were signs of pneumonia. One of the patients with septicaemia who did not respond to treatment proved to have Enterobacter aerogetnes in the blood for which the MIC of cefoxitin was greater than 80 mg/1. The other had an intra-abdominal abscess associated with biliary sepsis and he remained feverish and unwell with a positive blood culture until the abscess was drained. He died four weeks after this operation and necropsy showed carcinoma of the pancreas with metastases in the liver.
PHARMACOLOGICAL FINDINGS
One gram of cefoxitin given intravenously to two patients produced serum concentrations of 58 and 73 mg/l respectively after five minutes. Five minutes after 2 g cefoxitin was given by intravenous bolus injection peak serum concentrations were measured,in five patients and were 130, 140, 230, 305, and 340 mg/l (mean 229 mg/1) (table II) .
Serum concentrations remained satisfactory one hour after a dose and were adequate at two hours.
Urine cefoxitin concentrations in patients given 2-g doses ranged from 3500 mg/l to 25 000 mg 1 in the first hour after administration of the antibiotic (table III) . Cefoxitin concentrations in bile were very high (table IV) . The cefoxitin concentration in breast milk collected two hours after an intravenous dose of 1 g was 5-6 mg/l milk. Antibacterial activity was not demonstrable in the CSF of two patients given 2 g cefoxitin by intravenous injection one hour before lumbar puncture.
TOXICOLOGICAL EFFECTS
During cefoxitin treatment eight of 31 patients d.veloped transient and slight rises in serum hepatic transaminase concentrations, the maximum concentration being 100 IU/ml (normal range < 35 IU/ml). Two patients had proteinuria but there were no unexplained rises in serum urea or creatinine concentrations and no drug-related changes in blood count. One patient developed phlebitis during cefoxitin treatment but recovered rapidly when the intravenous drip site was changed. Five of the eight patients who were given cefoxitin intramuscularly complained of pain at the site of injection and in two of these this was intolerable. None of the patients developed a serious adverse reaction during cefoxitin treatment.
Discussion
With the exception of Pseudomonas aeruginosa, cefoxitin is highly active in vitro against most Gram-negative bacilli, and is more active than the "first generation" cephalosporins against these organisms.9 Cefoxitin has a broader antibacterial activity than most cephalosporins, being active against certain organisms that are resistant to this group of antibiotics, almost certainly because it is extremely stable in the presence of 5-lactamases produced by Gram-negative bacilli.3 The only cephalosporin comparable in this respect is cefuroxime, which also has a high degree of stability to 3-lactamases produced by Gram-negative organisms and is also completely stable to degradation by staphylococcal 5-lactamase.t0 Cefoxitin, however, is more active than cefuroxime against ampicillin-resistant Escherichia coli strains and indole-positive Proteus spp.tt Cefoxitin has a biological half life of 45 minutes as compared with cephalothin, the cephalosporin to which it is most closely related, which has a half life of only 25 minutes.' Our studies in patients have confirmed the findings of Kosmidis and his colleagues3 in volunteers that mean peak serum concentrations after an intravenous injection of 2 g of the antibiotic are over 200 mg/l, while urine concentrations with the same dose may exceed 20 000 mg/l. Urinary recovery of cefoxitin has been reported as varying between 780012 and 90°o3 as compared with 55 00 with cephalothin. We found that concentrations of cefoxitin in bile greatly exceed the MIC of most Gram-negative bacilli that inhabit the bowel. Hence probably cefoxitin will prove valuable for intra-abdominal and urinary tract infections and biliary sepsis. Cefoxitin was not detected in the CSF of one patient with non-inflammed meninges and one with meningoencephalitis, which accords with the poor meningeal penetration of other r3-lactam antibiotics.
In the clinical study cefoxitin cured 20 (64-50o) of a group of 31 patients with infections of the respiratory tract, urinary tract, peritoneal cavity, and septicaemia. Two of the patients with respiratory tract infection failed to respond but in both instances we could not culture an organism from a pretreatment sputum specimen and we cannot therefore assess the importance of this result. Of the two patients with urinary tract infection who failed to respond, one was elderly and had a uterine prolapse. The second was also an elderly woman with myxoedema who initially responded to cefoxitin but relapsed with the same infecting organism in the urine four weeks later. Both had residual urine in the bladder. All of the patients suffering from pyelonephritis were cured by cefoxitin but two of the eight patients with septicaemia failed to respond. All four patients with intra-abdominal sepsis were cured by cefoxitin treatment, combined in three with surgical drainage.
Cefoxitin appears to share with the cephalosporins and penicillins the property of rarely producing serious adverse reactions. Apart from transient derangement of liver function, and phlebitis in one patient, none of the patients developed untoward reactions to the antibiotic. Furthermore, it has been suggested"3 that cross-allergenicity between the cephalosporins and the cephamycins might not occur because of the differing chemical structures. There was no evidence of nephrotoxicity as demonstrated by increased serum urea or creatinine concentrations, both of which were measured before, during, and after treatment with cefoxitin.
The present uncontrolled study suggests that cefoxitin will have a place in the management of serious infections, particularly in the peritoneal cavity and biliary and renal tracts. Serum, urine, and bile concentrations of the antibiotic greatly exceed the MIC required for clinically important Gram-negative organisms.
